Dysfunction of any of these three glands can result in Meibomian gland dysfunction. A primary cause for this condition is not really the disease itself but rather the abnormal overproduction of sebum (the secreted liquid of glands). This is normally controlled by the hypothalamus-pituitary gland system which inhibits the secretion of oil. Rapidly increases the prevalence of meibomian gland dysfunction remains one of the critical factors aiding the development of the market. In fact, as per the Fellow of American College of Surgeons, meibomian gland disease, is one of the most common causes of dry eyes and around 50-70% of the elderly population has some degree of dry eye. Besides, as per the American Optometric Association’s study in 2017, over 16 million people in the U.S. were suffering from dry eye disease. Such factors can indeed stimulate growth of the U.S. meibomian gland dysfunction market.
When it comes to the drug type, Cyclosporine segment seems to be exhibiting positive traction in the U.S. meibomian gland dysfunction market. This is typically due to the fact that there is a rapid launch of novel products in the market. Recently, in August 2018, Sun Pharma received the U.S. Food and Drug Administration (FDA) approval for Cequa, indicated for increasing tear production in patients with dry eye disease. Recently, in April 2021, ThermaMEDx launched a self-healing, disposable, pre-moistened, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.
Read More: https://coherentmarketorientedblogs.blogspot.com/2021/07/us-meibomian-gland-dysfunction-market.html
